• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Artificial Coma Medically Induced Coma Companies

    ID: MRFR/HC/10745-HCR
    132 Pages
    Garvit Vyas
    October 2025

    The induction of a medically induced coma, also known as therapeutic hypothermia or targeted temperature management, is a medical intervention used to manage severe medical conditions such as traumatic brain injury, cardiac arrest, and certain neurological conditions. While the process involves the use of sedatives and cooling techniques to lower the body's temperature, there isn't a specific industry focused solely on artificial coma. However, companies involved in critical care, medical devices, and neurology may offer products or technologies related to therapeutic hypothermia. 

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    ReportInfographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Artificial Coma Medically Induced Coma Market

    Artificial Coma/Medically Induced Coma Key Companies

     

    Latest Artificial Coma/Medically Induced Coma Companies Update


    Bardem Pharmaceuticals, a rising player in the field, received a breakthrough designation from the FDA for its novel drug BPD-123 for inducing and maintaining MIC. This drug aims to offer improved control and reduced side effects compared to traditional barbiturates.


    Medtronic, a leading medical device company, introduced its BrainSense system, designed to monitor brain activity and vital signs in patients under MIC. This AI-powered system aims to provide real-time insights for better decision-making and improved patient outcomes.


    Researchers from MIT and Harvard Medical School published a study in Nature Medicine demonstrating a novel technique for controlled awakening from MIC. This method utilizes targeted electrical stimulation to specific brain regions, potentially leading to safer and faster recovery.


    Several clinical trials are underway exploring the potential of MIC in treating conditions beyond its traditional use for intracranial hypertension and status epilepticus. These include investigations for treating severe traumatic brain injuries, drug-resistant epilepsy, and even certain neurodegenerative diseases.


    List of Artificial Coma/Medically Induced Coma Key Companies in the Market



    • Piramal Group

    • Teva Pharmaceutical Industries Ltd.

    • Hikma Pharmaceuticals, Fresenius Se & Co Kgaa

    • Astrazeneca Plc

    • Reddy’s Laboratory

    • Pfizer Inc.

    • Viatris Inc. (Mylan N.V)

    • Braun Melsungen Ag

    • Baxter International Inc.